{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang ZH"],"funding":["Intramural NIH HHS","National Eye Institute","Office of Dietary Supplements","NEI NIH HHS","Research to Prevent Blindness","Foundation Fighting Blindness","University of Utah","Foundation for the National Institutes of Health","National Heart, Lung, and Blood Institute","National Institutes of Health","National Heart Lung and Blood Institute Division of Intramural Research"],"pagination":["108411"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10692724"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(12)"],"pubmed_abstract":["Very-long-chain polyunsaturated fatty acids (VLCPUFAs; C24-38) constitute a unique class of PUFA that have important biological roles, but the lack of a suitable dietary source has limited research in this field. We produced an n-3 C24-28-rich VLCPUFA-oil concentrated from fish oil to study its bioavailability and physiological functions in C57BL/6J mice. The serum and retinal C24:5 levels increased significantly compared to control after a single-dose gavage, and VLCPUFAs were incorporated into the liver, brain, and eyes after 8-week supplementation. Dietary VLCPUFAs resulted in favorable cardiometabolic changes, and improved electroretinography responses and visual performance. VLCPUFA supplementation changed the expression of genes involved in PPAR signaling pathways. Further <i>in vitro</i> studies demonstrated that the VLCPUFA-oil and chemically synthesized C24:5 are potent agonists for PPARs. The multiple potential beneficial effects of fish oil-derived VLCPUFAs on cardiometabolic risk and eye health in mice support future efforts to develop VLCPUFA-oil into a supplemental therapy."],"journal":["iScience"],"pubmed_title":["Dietary fish oil enriched in very-long-chain polyunsaturated fatty acid reduces cardiometabolic risk factors and improves retinal function."],"pmcid":["PMC10692724"],"funding_grant_id":["ZIAEY000450","R01 EY034497","ZIA EY000546","EY14800","P30 EY014800","EY34497","ZIAEY00546","ZIA EY000450"],"pubmed_authors":["Yamazaki I","Arunkumar R","Swenson RE","Yang ZH","Rojulpote KV","Kun JF","Decot H","Bernstein PS","Swaroop A","Remaley AT","Gorusupudi A","Tang J","Sato S","Mondal AK","Koch H","Lydic TA","Yu ZX","Yamaguchi H","Lin AB","Brock DC","Shi ZD","Pryor M"],"additional_accession":[]},"is_claimable":false,"name":"Dietary fish oil enriched in very-long-chain polyunsaturated fatty acid reduces cardiometabolic risk factors and improves retinal function.","description":"Very-long-chain polyunsaturated fatty acids (VLCPUFAs; C24-38) constitute a unique class of PUFA that have important biological roles, but the lack of a suitable dietary source has limited research in this field. We produced an n-3 C24-28-rich VLCPUFA-oil concentrated from fish oil to study its bioavailability and physiological functions in C57BL/6J mice. The serum and retinal C24:5 levels increased significantly compared to control after a single-dose gavage, and VLCPUFAs were incorporated into the liver, brain, and eyes after 8-week supplementation. Dietary VLCPUFAs resulted in favorable cardiometabolic changes, and improved electroretinography responses and visual performance. VLCPUFA supplementation changed the expression of genes involved in PPAR signaling pathways. Further <i>in vitro</i> studies demonstrated that the VLCPUFA-oil and chemically synthesized C24:5 are potent agonists for PPARs. The multiple potential beneficial effects of fish oil-derived VLCPUFAs on cardiometabolic risk and eye health in mice support future efforts to develop VLCPUFA-oil into a supplemental therapy.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-05-28T08:57:15.613Z","creation":"2025-05-18T10:37:54.649Z"},"accession":"S-EPMC10692724","cross_references":{"pubmed":["38047069"],"doi":["10.1016/j.isci.2023.108411"]}}